An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Clinical trial NCT05505916 · COMPLETED

Trial details

NCT number

NCT05505916

Sponsor

KalVista Pharmaceuticals, Ltd.

Status

COMPLETED

Phase

Phase 3

Study type

INTERVENTIONAL

Start date

2022-10-24

Primary completion

2026-05-27

Enrollment

145

View on ClinicalTrials.gov